Jones R N, Barry A L
Clinical Microbiology Institute, Tualatin, Oregon.
Diagn Microbiol Infect Dis. 1989 Mar-Apr;12(2):143-7. doi: 10.1016/0732-8893(89)90005-9.
One hundred Gram-positive bacteremia organisms from five important genus groups were tested against 10 newer beta-lactams. Ceftazidime was significantly less active (50% of strains at less than or equal to 8 micrograms/ml) compared to other cephalosporins. The penems (FCE-22101 and HRE-664) and imipenem were each superior to the cephalosporins with 92-93% inhibition of strains. A novel fused co-drug of fleroxacin and desacetyl-cefotaxime, Ro 23-9424, was 100% effective against these Gram-positive pathogens at less than or equal to 8 micrograms/ml. Several of these compounds should receive consideration for clinical trials for empiric therapy among neutropenic patient infections where Gram-positive pathogens may be more prevalent.
对来自五个重要菌属组的100株革兰氏阳性菌血症病原体进行了10种新型β-内酰胺类药物的测试。与其他头孢菌素相比，头孢他啶的活性明显较低（50%的菌株在小于或等于8微克/毫升时）。青霉烯类药物（FCE-22101和HRE-664）和亚胺培南对菌株的抑制率均高于头孢菌素，分别为92%-93%。一种新型的氟罗沙星与去乙酰头孢噻肟的融合联合药物Ro 23-9424在小于或等于8微克/毫升时对这些革兰氏阳性病原体的有效率为100%。在革兰氏阳性病原体可能更为普遍的中性粒细胞减少患者感染的经验性治疗临床试验中，应考虑使用其中几种化合物。
